HHS lets compounding pharmacies make six unapproved peptides while it works on a formal rule, over FDA objections
The Department of Health and Human Services is giving compounding pharmacies a temporary green light to make six peptides while the agency continues to work on a formal rule change, NBC News reported. MarketWatch reported that the government will not take action against pharmacies that make six of the popular wellness products, including BPC-157 and TB-500. The New York Times reported on Wednesday, Oct. 28, that the move is a unilateral declaration by Health Secretary Robert F. Kennedy Jr. and that the FDA had advised against it. AP reported that FDA scientists opposed the effort to ease access to peptides. The New York Times said the injections are promoted by online influencers.
Peptides are short chains of amino acids, and NBC News and The New York Times describe the ones at issue as unapproved. Compounding pharmacies normally make customized medicines, and MarketWatch reported that the government will not take action against pharmacies that make these six products. NBC News described the step as temporary while a formal rule change is worked on.
The peptides are not FDA-approved, as the reports cited describe them. A doctor can explain the risks of any injection before you decide.
The administration's side, as the Times describes Kennedy's action, is a unilateral declaration to make the injections widely available while a formal rule is developed.
The critics' side, as AP and the New York Times report, is that FDA scientists opposed the move and the agency advised against it.
Confirmed across outlets: HHS temporarily allowed compounding of six peptides and the FDA had advised against it. Not confirmed: the timeline for the formal rule, how long the permission lasts and any legal challenge. Watch for the formal proposal and for medical groups' responses.
DailyDrop U.S. No. 24 · October 28, 2026 · Evening